Africa is a pivotal region for the development of adult and paediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programmes. The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.
Vaccine development faces its own challenges associated with local immunisation recommendations as well as stringent cold chain management. ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, whilst complying in full with international clinical research guidelines.
ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharmaceutical companies. ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 percent growth rate over the 5-year period from 2006 to 2011. It was one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.
Commenting on the opening of ClinTec’s Malawi operations, Dr Rabinder Buttar stated: “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organisations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs”.
About ClinTec International
ClinTec International is a global clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in over 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and Africa, Central and South Africa, Latin America, Asia and the US.
In addition to ClinTec International’s extensive expertise in oncology, the organisation has also conducted over 400 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process. The organisation’s range of services includes Clinical Monitoring, Project Management, Regulatory Affairs, Medical Writing, Data Management, Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.
For further information please contact:
Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or bbal@clintec.com
For more information about ClinTec, please visit www.clintec.com
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3838 or e-mail: t.jervis@defacto.com
